BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 12867014)

  • 1. [Cytogenetic risk categories in acute myeloid leukemia: a comparison between MRC (Medical Research Council) and SWOG (Southwest Oncology Group) models)].
    Martín Ramos ML; López Pastor M; de la Serna Torroba J; Ayala R; García Alonso L; Barreiro Miranda E
    Med Clin (Barc); 2003 Jun; 121(4):121-5. PubMed ID: 12867014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission.
    Chalandon Y; Barnett MJ; Horsman DE; Conneally EA; Nantel SH; Nevill TJ; Nitta J; Shepherd JD; Sutherland HJ; Toze CL; Hogge DE
    Biol Blood Marrow Transplant; 2002; 8(8):435-43. PubMed ID: 12234169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.
    Grimwade D; Walker H; Oliver F; Wheatley K; Harrison C; Harrison G; Rees J; Hann I; Stevens R; Burnett A; Goldstone A
    Blood; 1998 Oct; 92(7):2322-33. PubMed ID: 9746770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups.
    Schoch C; Kern W; Schnittger S; Büchner T; Hiddemann W; Haferlach T
    Haematologica; 2004 Sep; 89(9):1082-90. PubMed ID: 15377469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.
    Grimwade D; Walker H; Harrison G; Oliver F; Chatters S; Harrison CJ; Wheatley K; Burnett AK; Goldstone AH;
    Blood; 2001 Sep; 98(5):1312-20. PubMed ID: 11520776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
    Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
    Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognostic significance of cytogenetic changes in patients with acute myeloid leukemia (AML). (Analysis of results in 105 patients treated at the Hemato-oncology Clinic of the University Hospital in Olomouc from 1997 to 2000].
    Jarosová M; Indrák K; Holzerová M; Hubácek J; Faber E; Papajík T; Raida L; Szotkowski T; Knotková R; Hlusí T; Jedlicková K; Pikalová Z; Sulovská I
    Vnitr Lek; 2001 Sep; 47 Suppl 1():8-14. PubMed ID: 11693065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML.
    Schoch C; Kern W; Schnittger S; Hiddemann W; Haferlach T
    Leukemia; 2004 Jan; 18(1):120-5. PubMed ID: 14586477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
    Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
    Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effectiveness analysis of HA based triple-drug regimen as induction chemotherapy in the treatment of acute myeloid leukemia and its relationship with karyotype].
    Mi YC; Xue YP; Yu WJ; Liu SH; Zhao YZ; Meng QX; Bian SG; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2005 Dec; 26(12):705-9. PubMed ID: 16620570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?
    Larson RA
    Best Pract Res Clin Haematol; 2007 Mar; 20(1):29-37. PubMed ID: 17336252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytogenetic risk grouping by the monosomal karyotype classification is superior in predicting the outcome of acute myeloid leukemia undergoing allogeneic stem cell transplantation in complete remission.
    Hemmati PG; Schulze-Luckow A; Terwey TH; le Coutre P; Vuong LG; Dörken B; Arnold R
    Eur J Haematol; 2014 Feb; 92(2):102-10. PubMed ID: 24138573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytogenetic abnormalities and monosomal karyotypes in children and adolescents with acute myeloid leukemia: correlations with clinical characteristics and outcome.
    Manola KN; Panitsas F; Polychronopoulou S; Daraki A; Karakosta M; Stavropoulou C; Avgerinou G; Hatzipantelis E; Pantelias G; Sambani C; Pagoni M
    Cancer Genet; 2013 Mar; 206(3):63-72. PubMed ID: 23411131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [AML treatment strategy based on cytogenetic abnormalities and somatic mutations].
    Imai Y
    Rinsho Ketsueki; 2015 Oct; 56(10):1932-41. PubMed ID: 26458431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy of acute myeloid leukemia: towards a patient-oriented, risk-adapted approach.
    Mandelli F; Petti MC; Lo Coco F
    Haematologica; 1998 Nov; 83(11):1015-23. PubMed ID: 9864924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multivariate analyses of prognostic factors in acute myeloid leukemia: relevance of cytogenetic abnormalities and CD34 expression.
    Junghanss C; Waak M; Knopp A; Kleine HD; Kundt G; Leithäuser M; Hilgendorf I; Wolff D; Casper J; Freund M
    Neoplasma; 2005; 52(5):402-10. PubMed ID: 16151585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia.
    Fruchart C; Lenormand B; Bastard C; Boulet D; Lesesve JF; Callat MP; Stamatoullas A; Monconduit M; Tilly H
    Am J Hematol; 1996 Nov; 53(3):175-80. PubMed ID: 8895688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia: analysis of prognostic factors.
    Stasi R; Venditti A; Del Poeta G; Aronica G; Dentamaro T; Cecconi M; Stipa E; Scimò MT; Masi M; Amadori S
    Cancer; 1996 Jun; 77(12):2476-88. PubMed ID: 8640696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype.
    Breems DA; Van Putten WL; De Greef GE; Van Zelderen-Bhola SL; Gerssen-Schoorl KB; Mellink CH; Nieuwint A; Jotterand M; Hagemeijer A; Beverloo HB; Löwenberg B
    J Clin Oncol; 2008 Oct; 26(29):4791-7. PubMed ID: 18695255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction chemotherapy versus palliative treatment for acute myeloid leukemia in a consecutive cohort of elderly patients.
    Colovic M; Colovic N; Radojkovic M; Stanisavljevic D; Kraguljac N; Jankovic G; Tomin D; Suvajdzic N; Vidovic A; Atkinson HD
    Ann Hematol; 2012 Sep; 91(9):1363-70. PubMed ID: 22592651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.